KR20250002689A - 신규한 억제제 - Google Patents

신규한 억제제 Download PDF

Info

Publication number
KR20250002689A
KR20250002689A KR1020247039667A KR20247039667A KR20250002689A KR 20250002689 A KR20250002689 A KR 20250002689A KR 1020247039667 A KR1020247039667 A KR 1020247039667A KR 20247039667 A KR20247039667 A KR 20247039667A KR 20250002689 A KR20250002689 A KR 20250002689A
Authority
KR
South Korea
Prior art keywords
alkyl
phenyl
compound
amino
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247039667A
Other languages
English (en)
Korean (ko)
Inventor
울리히 헤이서
토르스텐 호프만
잉게보르그 루이즈
안체 마이어
Original Assignee
비보리온 테라퓨틱스 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비보리온 테라퓨틱스 엔.브이. filed Critical 비보리온 테라퓨틱스 엔.브이.
Publication of KR20250002689A publication Critical patent/KR20250002689A/ko
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08Radicals containing only hydrogen and carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/40Unsubstituted amino or imino radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/121,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/1251,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020247039667A 2017-03-31 2018-04-03 신규한 억제제 Pending KR20250002689A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB1705263.0 2017-03-31
GBGB1705263.0A GB201705263D0 (en) 2017-03-31 2017-03-31 Novel inhibitors
KR1020197028930A KR102737532B1 (ko) 2017-03-31 2018-04-03 신규한 억제제
PCT/EP2018/058391 WO2018178384A1 (en) 2017-03-31 2018-04-03 Novel inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197028930A Division KR102737532B1 (ko) 2017-03-31 2018-04-03 신규한 억제제

Publications (1)

Publication Number Publication Date
KR20250002689A true KR20250002689A (ko) 2025-01-07

Family

ID=58682483

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247039667A Pending KR20250002689A (ko) 2017-03-31 2018-04-03 신규한 억제제
KR1020197028930A Active KR102737532B1 (ko) 2017-03-31 2018-04-03 신규한 억제제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197028930A Active KR102737532B1 (ko) 2017-03-31 2018-04-03 신규한 억제제

Country Status (13)

Country Link
US (3) US11339152B2 (https=)
EP (1) EP3601269A1 (https=)
JP (3) JP7674811B2 (https=)
KR (2) KR20250002689A (https=)
CN (2) CN110719910B (https=)
AU (2) AU2018246382C1 (https=)
CA (2) CA3221839A1 (https=)
EA (1) EA201992120A1 (https=)
GB (1) GB201705263D0 (https=)
IL (3) IL297534A (https=)
MX (2) MX2019011544A (https=)
WO (1) WO2018178384A1 (https=)
ZA (1) ZA201905811B (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2536650A (en) 2015-03-24 2016-09-28 Augmedics Ltd Method and system for combining video-based and optic-based augmented reality in a near eye display
US12521201B2 (en) 2017-12-07 2026-01-13 Augmedics Ltd. Spinous process clamp
US12458411B2 (en) 2017-12-07 2025-11-04 Augmedics Ltd. Spinous process clamp
EP3787543A4 (en) 2018-05-02 2022-01-19 Augmedics Ltd. REGISTRATION OF A FIDUCIAL MARKER FOR AN AUGMENTED REALITY SYSTEM
CR20210163A (es) * 2018-10-05 2021-06-24 Pfizer Inhibidores de pde4 que contienen boro
US11766296B2 (en) 2018-11-26 2023-09-26 Augmedics Ltd. Tracking system for image-guided surgery
WO2020142764A1 (en) * 2019-01-06 2020-07-09 Psomagen Inc. Htra inhibitors and caga inhibitors and use thereof
US11980506B2 (en) 2019-07-29 2024-05-14 Augmedics Ltd. Fiducial marker
US12178666B2 (en) 2019-07-29 2024-12-31 Augmedics Ltd. Fiducial marker
US11382712B2 (en) 2019-12-22 2022-07-12 Augmedics Ltd. Mirroring in image guided surgery
AU2021208943B2 (en) 2020-01-17 2023-10-05 Daegu-Gyeongbuk Medical Innovation Foundation Novel compound, preparation method thereof, and use thereof
KR102433502B1 (ko) * 2020-01-17 2022-08-18 재단법인 대구경북첨단의료산업진흥재단 신규 화합물, 이의 제조방법 및 이의 용도
US11389252B2 (en) 2020-06-15 2022-07-19 Augmedics Ltd. Rotating marker for image guided surgery
US12502163B2 (en) 2020-09-09 2025-12-23 Augmedics Ltd. Universal tool adapter for image-guided surgery
US12239385B2 (en) 2020-09-09 2025-03-04 Augmedics Ltd. Universal tool adapter
WO2022086920A1 (en) * 2020-10-20 2022-04-28 Blacksmith Medicines, Inc. Glutaminyl-peptide cyclotransferase like (qpctl) protein inhibitors and uses thereof
AR124297A1 (es) * 2020-12-10 2023-03-15 Bayer Ag Ácidos pirazol piperidin carboxílicos sustituidos
US11896445B2 (en) 2021-07-07 2024-02-13 Augmedics Ltd. Iliac pin and adapter
US12150821B2 (en) 2021-07-29 2024-11-26 Augmedics Ltd. Rotating marker and adapter for image-guided surgery
US12475662B2 (en) 2021-08-18 2025-11-18 Augmedics Ltd. Stereoscopic display and digital loupe for augmented-reality near-eye display
CN117567435A (zh) * 2022-01-30 2024-02-20 上海市第十人民医院 谷氨酰胺环化酶抑制剂及其应用
WO2023205173A1 (en) * 2022-04-20 2023-10-26 Blacksmith Medicines, Inc. Substituted piperidines and substituted tetrahydropyridines as immune-modulating compounds
WO2023203521A1 (en) 2022-04-21 2023-10-26 Augmedics Ltd. Systems and methods for medical image visualization
CN114560817B (zh) * 2022-04-25 2022-10-25 北京大学第三医院(北京大学第三临床医学院) 一种用于抑制纤维化的小分子药物及其应用
AR130003A1 (es) 2022-08-03 2024-10-23 Boehringer Ingelheim Int Derivados de piperidinilpiridinilcarbonitrilo como inhibidores de glutaminil-péptido ciclotransferasa y proteína tipo glutaminil-péptido ciclotransferasa
JP2025531829A (ja) 2022-09-13 2025-09-25 オーグメディックス リミテッド 画像誘導医療介入のための拡張現実アイウェア
CN120379972A (zh) * 2022-12-20 2025-07-25 深圳湾实验室 一种靶向usp1的小分子抑制剂及其应用
KR20250121039A (ko) 2022-12-22 2025-08-11 베링거 인겔하임 인터내셔날 게엠베하 글루타미닐-펩타이드 사이클로트랜스퍼라제 및 글루타미닐-펩타이드 사이클로트랜스퍼라제 유사 단백질의 억제제로서 페닐피페리딘 유도체
CR20250377A (es) 2023-03-13 2025-11-19 Boehringer Ingelheim Int Derivados de fenilpiperidina como inhibidores de la glutaminil-péptido ciclotransferasa y proteína similar a glutaminil-péptido ciclotransferasa
IL326207A (en) 2023-08-04 2026-03-01 Boehringer Ingelheim Int History of piperidinylpyridinylcarbonitrile as inhibitors of glutaminyl-peptide cyclotransferase and glutaminyl-peptide cyclotransferase-like protein
US20250059166A1 (en) 2023-08-04 2025-02-20 Boehringer Ingelheim International Gmbh Piperidinylpyridinylcarbonitrile derivatives as inhibitors of glutaminyl-peptide cyclotransferase and glutaminyl-peptide cyclotransferase like protein
IL326386A (en) 2023-08-14 2026-04-01 Boehringer Ingelheim Int History of piperidinylpyridinylcarbonitrile as inhibitors of glutaminyl-peptide cyclotransferase and glutaminyl-peptide cyclotransferase-like protein
CN117538462B (zh) * 2024-01-10 2024-03-26 地奥集团成都药业股份有限公司 一种氨氯地平贝那普利胶囊有关物质的检测方法
WO2025240620A1 (en) * 2024-05-14 2025-11-20 Pronovo Therapeutics Inc. Selective dual agonists of muscarinic 1 and 4 receptors and therapeutic uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0640599T3 (da) * 1993-08-26 1998-09-28 Ono Pharmaceutical Co 4-Aminopyrimidin-derivater
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US7064215B2 (en) * 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
US7642278B2 (en) * 2001-07-03 2010-01-05 Novartis Vaccines And Diagnostics, Inc. Indazole benzimidazole compounds
US8673924B2 (en) * 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
WO2005004818A2 (en) * 2003-07-09 2005-01-20 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
EP1781659B1 (en) * 2003-07-16 2008-11-05 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
AU2005205201B2 (en) * 2004-01-12 2011-05-12 Merck Serono Sa Thiazole derivatives and use thereof
EP1718306A2 (en) * 2004-02-20 2006-11-08 Chiron Corporation Modulation of inflammatory and metastatic processes
MX2007000631A (es) * 2004-07-16 2007-03-30 Sunesis Pharmaceuticals Inc Tienopirimidinas utiles como inhibidores de aurora cinasa.
JP2008508358A (ja) * 2004-08-02 2008-03-21 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド アリール−アミノ置換ピロロピリミジンマルチキナーゼ阻害化合物
GB0520958D0 (en) * 2005-10-14 2005-11-23 Cyclacel Ltd Compound
WO2007067537A1 (en) * 2005-12-07 2007-06-14 Osi Pharmaceuticals, Inc. Pyrrolopyridine kinase inhibiting compounds
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
AR060358A1 (es) * 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
US7893058B2 (en) * 2006-05-15 2011-02-22 Janssen Pharmaceutica Nv Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
CN101511800B (zh) * 2006-07-14 2013-02-27 坎莫森特里克斯公司 三唑基苯基苯磺酰胺
JP2010514693A (ja) * 2006-12-22 2010-05-06 ノバルティス アーゲー Pdk1阻害のためのキナゾリン
CN101568529A (zh) * 2006-12-22 2009-10-28 诺瓦提斯公司 作为cdk抑制剂、用于治疗癌症、炎症和病毒感染的杂芳基-杂芳基化合物
WO2008128986A1 (en) * 2007-04-18 2008-10-30 Probiodrug Ag Urea derivatives as glutaminyl cyclase inhibitors
WO2008128984A1 (en) * 2007-04-20 2008-10-30 Probiodrug Ag Aminopyrimidine derivatives as glutaminyl cyclase inhibitors
JP5611826B2 (ja) * 2007-09-04 2014-10-22 ザ スクリプス リサーチ インスティテュート タンパク質キナーゼ阻害剤としての置換されたピリミジニル−アミン
EP2326627A1 (en) * 2008-08-20 2011-06-01 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CN102186475B (zh) * 2008-09-04 2016-08-03 前体生物药物股份公司 新抑制剂
JP5934645B2 (ja) * 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
JP6026284B2 (ja) * 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) * 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) * 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
JP2014500254A (ja) * 2010-11-09 2014-01-09 セルゾーム リミティッド Tyk2阻害剤としてのピリジン化合物およびそのアザ類似体
NO2638031T3 (https=) * 2010-11-10 2018-03-10
US8785459B2 (en) 2011-12-27 2014-07-22 Development Center For Biotechnology Quinazoline compounds as kinase inhibitors
EP2844652B1 (en) * 2012-05-03 2019-03-13 Genentech, Inc. Pyrazole aminopyrimidine derivatives as lrrk2 modulators
WO2014081718A1 (en) * 2012-11-20 2014-05-30 Genentech, Inc. Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
MX367855B (es) * 2013-03-15 2019-09-09 Probiodrug Ag Inhibidores novedosos.
MA40957A (fr) * 2014-10-09 2017-09-19 Biomarin Pharm Inc Inhibiteurs de biosynthèse d'héparane sulfate pour traiter des maladies
CA2979302A1 (en) * 2015-05-13 2016-11-17 Selvita S.A. Substituted quinoxaline derivatives
EP3334733A1 (en) * 2015-08-10 2018-06-20 Pfizer Inc 3-indol substituted derivatives, pharmaceutical compositions and methods for use
SG11201804901WA (en) * 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
US10034861B2 (en) * 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors

Also Published As

Publication number Publication date
AU2018246382A1 (en) 2019-10-17
MX2019011544A (es) 2019-12-16
BR112019019553A2 (pt) 2020-04-22
JP2020512373A (ja) 2020-04-23
AU2022246405A1 (en) 2022-10-27
WO2018178384A1 (en) 2018-10-04
NZ757601A (en) 2023-02-24
IL269196B2 (en) 2024-04-01
KR20190136005A (ko) 2019-12-09
CN110719910A (zh) 2020-01-21
JP7674811B2 (ja) 2025-05-12
IL307911A (en) 2023-12-01
AU2018246382B2 (en) 2022-06-16
KR102737532B1 (ko) 2024-12-04
JP7589191B2 (ja) 2024-11-25
CA3221839A1 (en) 2018-10-04
MX2022007317A (es) 2022-07-13
IL307911B1 (en) 2026-03-01
IL269196B1 (en) 2023-12-01
JP2024153639A (ja) 2024-10-29
IL297534A (en) 2022-12-01
EP3601269A1 (en) 2020-02-05
US20220274977A1 (en) 2022-09-01
US11339152B2 (en) 2022-05-24
NZ792694A (en) 2025-10-31
US12384772B2 (en) 2025-08-12
JP2022110130A (ja) 2022-07-28
IL269196A (en) 2019-11-28
ZA201905811B (en) 2020-06-24
US20260001873A1 (en) 2026-01-01
CN110719910B (zh) 2023-07-21
CA3057783A1 (en) 2018-10-04
CN117024352A (zh) 2023-11-10
US20200377493A1 (en) 2020-12-03
GB201705263D0 (en) 2017-05-17
AU2018246382C1 (en) 2024-07-04
AU2022246405B2 (en) 2024-08-01
EA201992120A1 (ru) 2020-01-29

Similar Documents

Publication Publication Date Title
KR102737532B1 (ko) 신규한 억제제
EP2142514B1 (en) Thiourea derivatives as glutaminyl cyclase inhibitors
KR101694556B1 (ko) 신규한 억제제
KR101790806B1 (ko) 글루타미닐 사이클라제(qc, ec 2.3.2.5)의 헤테로사이클릭 억제제
EP2142515B1 (en) Nitrovinyl-diamine derivatives as glutaminyl cyclase inhibitors
EP2118101A1 (en) Imidazo [1,5-a] pyridine derivatives as inhibitors of glutaminyl cyclase
DK2686313T3 (en) Benzimidazole derivatives as inhibitors of glutaminyl cyclase
EP2142513A1 (en) Nitrovinyl-diamine derivatives as glutaminyl cyclase inhibitors
WO2008128983A1 (en) Cyano-guanidine derivatives as glutaminyl cyclase inhibitors
HK40102998A (zh) 新的抑制剂
BR112019019553B1 (pt) Composto, seu uso, e composição farmacêutica
HK40022733A (en) Novel inhibitors
BR122022013928B1 (pt) Composto de fórmula (i), composição farmacêutica e seus usos
EA043556B1 (ru) Полициклические ингибиторы глутаминилциклазы
HK40022733B (zh) 新的抑制剂

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20241128

Application number text: 1020197028930

Filing date: 20191001

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241213

Comment text: Request for Examination of Application

PG1501 Laying open of application